This year’s Ergomed AGM was held at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH starting at 9.30am on Friday 16 June 2017. For Investors who are unfamiliar with the company, Ergomed is a hybrid Pharmaceutical Services company offering a complete Clinical Development service for investigational drugs and a Pharmacovigilance monitoring service for marketed products. What makes Ergomed fairly unique amongst its peers is its co-development model, whereby it shares the cost of clinicals trials on new medicines that it runs on behalf of clients in exchange for a royalty (typically 10 – 15%) on sales. Ergomed was founded in 1997 and listed on AIM in July 2014 raising £11m at 160p/share valuing the company at £46m. The number of shares has increased from 28.75m at
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.